A2ARAlpha-2 Adrenergic Receptors
References in periodicals archive ?
The combination of our industry leading allosteric modulator drug discovery platform with Viva s cutting-edge structural biology expertise is expected to facilitate the development of a selective and potent oral small molecule for the activation of A2AR, a compelling new mechanism of action to address multiple inflammatory diseases, including certain rare disease indications with significant unmet medical needs.
Under the terms of the agreement, Viva Biotech will provide a fully-integrated structural biology discovery service to Addex to deliver high resolution crystal structures of A2AR in complex with positive allosteric modulators (PAMs) that were identified using Addex proprietary HTS technologies.
Addex' A2AR PAMs constitute the first examples of chemically tractable, selective, oral small molecule compounds with functional activity on this important GPCR target till date.